These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 20651609)

  • 1. Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.
    Adjei AA; Salavaggione OE; Mandrekar SJ; Dy GK; Ziegler KL; Endo C; Molina JR; Schild SE; Adjei AA
    J Thorac Oncol; 2010 Sep; 5(9):1346-53. PubMed ID: 20651609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
    Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
    Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.
    Adjei AA; Mandrekar SJ; Dy GK; Molina JR; Adjei AA; Gandara DR; Ziegler KL; Stella PJ; Rowland KM; Schild SE; Zinner RG
    J Clin Oncol; 2010 Feb; 28(4):614-9. PubMed ID: 19841321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
    Grønberg BH; Lund-Iversen M; Strøm EH; Brustugun OT; Scott H
    J Thorac Oncol; 2013 Oct; 8(10):1255-64. PubMed ID: 24457236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer.
    Dy GK; Bogner PN; Tan W; Demmy TL; Farooq A; Chen H; Yendamuri SS; Nwogu CE; Bushunow PW; Gannon J; Adjei AA; Adjei AA; Ramnath N
    J Thorac Oncol; 2014 Feb; 9(2):222-30. PubMed ID: 24419420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
    Xiong L; Cheng J; Gao J; Wang J; Liu X; Wang L
    Clin Lung Cancer; 2013 Jul; 14(4):433-9. PubMed ID: 23522953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.
    Smit EF; Socinski MA; Mullaney BP; Myrand SP; Scagliotti GV; Lorigan P; Reck M; Ciuleanu T; von Pawel J; Karaseva NA; Szczesna A; Ohannesian D; Powell E; Hozak RR; Hong S; Guba SC; Thatcher N
    Ann Oncol; 2012 Jul; 23(7):1723-9. PubMed ID: 22186609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum.
    Ryu JS; Shin ES; Nam HS; Yi HG; Cho JH; Kim CS; Kim HJ; Lee JE
    J Thorac Oncol; 2011 Aug; 6(8):1320-9. PubMed ID: 21642870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
    Bylicki O; Ferlay C; Chouaid C; Lavolé A; Barlési F; Dubos C; Westeel V; Créquit J; Corre R; Vergnenègre A; Monnet I; Le Caer H; Fournel P; Vaylet F; Falchero L; Poudenx M; Linard P; Pérol D; Zalcman G; Pérol M
    J Thorac Oncol; 2013 Jul; 8(7):906-14. PubMed ID: 23591160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.
    Gridelli C; Rossi A; Di Maio M; Leo S; Filipazzi V; Favaretto AG; Burgio MA; Cinieri S; Bianco R; Ciardiello F; Cavanna L; Bordonaro R; Costanzo R; Sandomenico C; Gallo C; Perrone F; Morabito A
    Clin Lung Cancer; 2014 Mar; 15(2):166-70. PubMed ID: 24418693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
    Smit EF; Burgers SA; Biesma B; Smit HJ; Eppinga P; Dingemans AM; Joerger M; Schellens JH; Vincent A; van Zandwijk N; Groen HJ
    J Clin Oncol; 2009 Apr; 27(12):2038-45. PubMed ID: 19307503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status.
    Dy GK; Molina JR; Qi Y; Ansari R; Thomas S; Ross HJ; Soori G; Anderson D; Aubry MC; Meyers J; Adjei AA; Mandrekar S; Adjei AA
    J Thorac Oncol; 2014 Aug; 9(8):1146-53. PubMed ID: 25157767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer.
    Cohen MH; Justice R; Pazdur R
    Oncologist; 2009 Sep; 14(9):930-5. PubMed ID: 19737998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer.
    Ortuzar W; Hanna N; Pennella E; Peng G; Langer C; Monberg M; Scagliotti G
    Clin Lung Cancer; 2012 Jan; 13(1):24-30. PubMed ID: 21831719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial.
    Treat J; Bonomi P; McCleod M; Christiansen NP; Mintzer DM; Monberg MJ; Ye Z; Chen R; Obasaju CK
    Lung Cancer; 2006 Jul; 53(1):77-83. PubMed ID: 16730854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer.
    Wu YL; Lu S; Cheng Y; Zhou C; Wang M; Qin S; Lu Y; Zhang Y; Zhu Y; Song X; Wang X; Barraclough H; Zhang X; Chi H; Orlando M
    Lung Cancer; 2014 Sep; 85(3):401-7. PubMed ID: 25082564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
    Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
    Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial.
    Yang CH; Simms L; Park K; Lee JS; Scagliotti G; Orlando M
    J Thorac Oncol; 2010 May; 5(5):688-95. PubMed ID: 20150825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.
    Syrigos KN; Vansteenkiste J; Parikh P; von Pawel J; Manegold C; Martins RG; Simms L; Sugarman KP; Visseren-Grul C; Scagliotti GV
    Ann Oncol; 2010 Mar; 21(3):556-561. PubMed ID: 19828561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A folylpoly-γ-glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for non-small cell lung cancer.
    Fukuda S; Oguri T; Kunii E; Sone K; Uemura T; Takakuwa O; Maeno K; Kanemitsu Y; Ohkubo H; Takemura M; Ito Y; Niimi A
    Lung Cancer; 2016 Dec; 102():15-20. PubMed ID: 27987582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.